Zydus Lifesciences launches ANVIMO
ANVIMO will be available in dosages of 240 mg and 480 mg
ANVIMO will be available in dosages of 240 mg and 480 mg
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
Standalone profit from operations for Q4-2024 were Rs. 108 crore
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
USFDA inspection at Emcure Pharmaceuticals API facility
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Subscribe To Our Newsletter & Stay Updated